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Carcinoembryonic antigen and some liver function tests (alkaline phosphatase, gamma-glutamyl-
transpeptidase, lactic dehydrogenase and cholinesterase) were evaluated in patients with primary
colorectal cancer in order to define their role in the pre-operative detection of liver metastases.
The records of 278 consecutive patients admitted to the Istituto Nazionale Tumori of Milan between
January 1982 and December 1983 who were suffering from primary invasive colo-rectal cancer and who
underwent laparotomy were retrospectively analyzed.
At laparotomy, liver metastases were found in 38 pts (13.7%). Considering single tests, CEA was the
most sensitive (71%); no single test was found to be reliably predictive, when the result was abnormal.
On the contrary, the normal value of each test was associated with a good prediction.
When we considered all the five tests together in the single patient their predictive value, when
abnormal, proved to be quite good only if four or five results were abnormal. On the other hand, liver
metastases in the presence of all normal tests were found only in two patients, so giving a negative
predictive value of about 97%.
So we conclude that, in the lack of an infallable imaging technique for liver evaluation, in the presence
of all normal tests any other investigation on the liver could be avoided. However, when liver tests are
pathologic, some other imaging technique should be performed in order to supply the surgeon with
information about the extent and the spread of the metastases.
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INTRODUCTION
The frequency of liver metastases (LM) at the time of initial surgical exploration for
primary colo-rectal cancer is estimated to be between 14% and 25% 1.
The increasing number of favourable reports on the efficacy of a surgical
approach and loco-regional chemotherapy for colo-rectal liver metastases
increases the importance of the pre-operative detection of secondlry lesions.
In spite of the use of various diagnostic modalities such as scintiscan, ultrasono-
graphy, CT scan and MNR, the pre-operative demonstration of metastases is often
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quite inaccurate, particularly when the lesions are small. It is generally considered
that the role of low-cost laboratory tests in the detection of LM is of limited value
and of minor importance in comparison with imaging procedures; nevertheless the
literature includes controversial results that are sometimes surprisingly good.
3-5
The aim of the present study was to verify the value of CEA and some
biochemical hepatic tests in the pre-operative detection of hepatic metastases in
patients with primary colo-rectal cancer.
MATERIAL AND METHODS
We analyzed retrospectively the records of 278 consecutive patients admitted to the
Istituto Nazionale Tumori between January 1982 and December 1983 with primary
colo-rectal cancer and who underwent laparotomy.
All cancers were invasive adenocarcinomas. In 38 patients (13.7%) LM were
assessed at laparotomy; 6 patients had synchronous extrahepatic metastases and
were considered to be in the group of patients without liver metastases. Table 1
reports the main characteristics of the series.
The laboratory tests examined were: plasma CEA, alkaline phosphatase (AP),
gamma glutamyl transpeptidase (GGT), lactic dehydrogenase (LDH) and cholines-
terase (CHE).
Serum CEA was determined using the radio immunoassay kit supplied by
Hoffmann-LaRoche, in which values between 0 and 10 nanograms per milliliter are
normal. The methods of determination of liver enzymes and the upper or lower
limits of normality used in our laboratory in 1982 and 1983 were the following:
AP: Szasz method; upper limit of normal 170 mU/ml.
GGT: Szasz method; upper limit for male 26 U/l, for female 18 U/1.
LDH: Wroblewski method; upper limit 240 mU/ml.
CHE: Ellman method; lower limit of normal 1900 U/1.
We have considered as pathologic those values exceeding the normal range
indicated by these methods. The tests were evaluated by calculating the sensitivity
(SE), the specificity (SP), the predictive value of a positive (pathologic) test (PVP),
the predictive value of a negative (normal) test (PVN) and the diagnostic accuracy
(DA).
SE is defined as the proportion of patients with LM testing positive (A/A + C)
where C is the number of false negative cases. SP is the proportion of patients
without LM testing negative (D/B + D) where B is the number of false positive
cases. PVP is the proportion of patients testing positive found with LM at
laparotomy (A/A + B). PVN is the proportion of patients testing negative proved
to be free ofLM at laparotomy (D/C + D). DA is defined as the proportion of cases
correctly diagnosed by the test (A + D/A + B + C +D) where B + C is the number
of cases erroneously diagnosed by the test.
The presence or absence of liver metastases was judsed at laparotomy by careful
inspection and palpation; biopsy for histology was taken whenever some alteration
on the gross examination of the liver was apparent. The extension of liver
involvement was classified according to the proposal of Gennari e al..
Preoperative liver evaluation was performed during that period at our Institution
by means or scintigraphy of ultrasonography.CEA AND ENZYMES IN LIVER METASTASES 31
Table 1 Main characteristics of the series.
Variable No. % M+ %M-
No. of pts 278 14 86
Sex Male 147 12 88
Female 131 15 85
Age Mean 58.6 59.1 58.8
Range 30-86 34-86 30-82
Site of primary:
colon recto-
sigmoid 170 12 88
rectum 106 15 85
multiple 2 50 50
Histologic type:
well diff. 40 12 88
mod. diff. 204 15 85
poorly diff. 11 18 82
other 23 4 96
Dukes A 30 3 97
B 134 6 94
C 102 24 76
undetermined +
D (liver excluded) 12 25 75
RESULTS
First, we evaluated the relation of each single test to LM and next the impact of all
the laboratory tests considered together in each case. Table 2 reports the results of
single tests.
The findings of the preoperative liver ultrasonography (US) performed in 113
patients, 22 having LM, have been reported for comparison.
The SE of US was 50%, the SP 90%; the PVP was 55% with a lower number of
false positive tests than any laboratory test examined. The PVN was quite similar to
the other tests considered and the DA was 82%.
Table 2 Analysis of single tests.
Variable Se. Sp. PVP. PVN. DA
CEA 71% 70% 30% 93% 70%
AP 32% 90% 35% 89% 82%
GGT 39% 85% 31% 89% 78%
LDH 51% 62% 18% 89% 61%
CHE 44% 81% 26% 90% 75%
US 50% 90% 55% 88% 82%
Se sensitivity PVP predictive value of a positive test
Sp specificity PVN predictive value of a negative test
DA diagnostic accuracy32 G. BONFANTI ETAL.
Table 3 analyzes the sensitivity of tests in relation to the metastatic involvement
of the liver. The direct connection between the positivity of the tests and the extent
ofLM is evident. In cases ofLM involving less than 25% of the parenchyma, CEA
was the most sensitive test (62%, 13 out of 21), whereas US (33%, 4 out of 12), and
liver function tests (SE ranging between 10% and 36%) failed frequently to identify
or suspect the presence of lesions.
Table 4 reports the range and median values of tests in the presence or absence of
metastases. From the observation of median values, we can infer that with the
exception of CEA, there was no difference between cases with and without
metastases and more than half the cases with LM showed normal values. It is
evident that the range of values is different in cases with and without LM, being
more extreme in the presence of LM, but we can observe consistent deviations in
cases without LM as well, particularly in CEA levels.
In 210 patients, where the evaluation was complete, it was possible to analyze the
relationship between all the laboratory tests and the presence or absence of LM
(Table 5). When all the tests (CEA and liver function tests) were normal the
probability of finding LM proved to be very low: in fact we observed only two false
negative cases (PVN 96.7%, with 95% confidence limits of 89%-99%). In these
two cases laparotomy revealed H1 metastases: the first had been investigated
preoperatively with hepatic CT scan, US and scintigraphy, and the second with
scintigraphy, but no examination was able to demonstrate the presence of second-
ary lesions.
Table 3 Sensitivity of tests in relation to the extent of liver metastases (Gennari’s classification).
H1 <25%) H2 (25-50%) H3 >50%)
Variable ratio % ratio % ratio %
CEA 13/21 62% 6/6 100% 6/8
A.P. 2/21 10% 2/8 25% 8/9
GGT 3/21 14% 3/8 38% 9/9
LDH 3/18 17% 6/8 75% 9/9
CHE 5/19 26% 4/8 50% 7/9
U.S. 4/12 33% 3/5 60% 4/5
75%
89%
100%
100%
78%
80%
Table 4 Range and median values of tests in the presence or absence of metastases.
With LM Without LM
Variable Median Median
(standard value) Range value Range value
CEA (< 10) 0-4953 41.9 0-188
A.P.(< 170) 16-1552 121.5 17-352
GGTm. (<26) 7-218 21 4-99
GGTf. (< 18) 4-1864 11.5 3-222
LDH (<240) 45-1523 241 55-389
CHE (> 1900) 1430-3260 1990 440-4600
2
114
21
10
223
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Table 5 Predictive values of abnormal tests in relation to their number.
No. abnormal tests M+/M- PVP PVN
One 10/68 12.8%
Two 6/33 15.4%
Three 5/17 22.7%
Four 4/1 80%
Five 5/0 100%
None 2/59 96.7%
95% confidence limits are 89%, 99%.
When one or more tests were abnormal, a direct relationship between the
number of abnormal tests and the detection of LM at laparotomy was evident, but
the number of false positive cases was quite high, up to three abnormal tests, and
became acceptably low in the presence of 4 or 5 abnormal tests.
With the aim of verifying the accuracy of our intraoperative liver evaluation, the
follow-up of patients with all normal tests and no evidence of LM at laparotomy
was analyzed. Two patients developed clinical evident LM within the first year of
follow-up, one after 10 months and the other after 12 months from operation.
Two other patients had LM in the second year of follow-up, another in the third
year and two thereafter.
In all, 7 patients out of 54 (13%) evaluable patients (five were lost to follow-up
within the second year) developed LM.
DISCUSSION
When dealing with new diagnostic methods for the detection of LM, there is often a
gap between initial encouraging clinical results and later disappointing results
obtained in routine use when retrospective studies are performed. However this
gap may stimulate investigation into simple, low-priced and objective tests, to
better defining their role and limits. Even with the systematic use of scintigraphy,
sonography, CT scan and MNR, the finding of a previously undetected LM at
laparotomy, is not an exception in clinical practice, and it is plain that the more the
results are unsatisfactory, the more the problem of costs cannot be disregarded.
The need to razionalize the use of methods in routine practice is then apparent.
In our retrospective series, 11 out of 22 patients who underwent ultrasonogra-
phy, (the test used now in routine screening in our Institution), showed LM at
laparotomy. The results were even poorer in small metastases (4 out of 12). In
other prospective series the sensitivity of ecography is between 70 and 90% 7-10, but
more than 50% of our patients with LM only had small lesions.
Moreover, it is well known that the accuracy of routine examination is poorer
compared with prospective studies.
The low-cost laboratory tests (CEA and liver function tests) have been widely
assessed for their diagnostic accuracy in predicting liver metastases from colo-rectal
cancer. It is well known that the CEA test usually increases in the presence of LM
and the elevation is related to the extent of metastases 3,11-13. The main limit of34 G. BONFANTI ETAL.
CEA in the prediction of LM is the high number of false positive cases, since it
increases frequently with primary lesions.
As regards liver function tests, the limits are" a they generally show a low
specificity, since they change in a number of other hepatic diseases; b at the same
time they have a low sensitivity, unless the liver is widely involved with metastases.
But the results reported in the literature are rather controversial with regard to
this point. Whereas most authors find a good sensitivity for massive involvement of
the liver but a number of false negative cases, as high as 90% for small lesions,
when testing AP 14-18, GGT 15,16 and LDH 18. Other investigators find a very high.
sensitivity (75 to 90%), even for small metastases, when testing AP 3,4 or GGT 4,5.
CEA and liver function tests have been studied in various combinations,
sometimes modifying the discriminant values between normal and pathologic.
Couples of tests, usually CEA and another, would demonstrate a better accuracy
than a single test 3,1, 19. In our experience, the accuracy of the surgical evaluation of
the liver at laparotomy appeared to be quite good, since no patients showed LM
before 10 months from operation and only two showed LM within one year. This is
not in conflict with recent reports
20, 22 about the accuracy of ultrasonography in the
detection of LM unrecognized by palpation, which is about 17%-29% of cases, if
we hypothesize a slow evolution of some small lesions deep in the parenchyma.
Therefore, we can suppose that the possible underestimation of LM in this series
did not influence the results in a relevant way.
In our series, the CEA test showed a better sensitivity than any other test,
ultrasonography included (Table 3). If we considered small lesions (Table 4), the
difference in sensitivity was even more apparent. The predictive value of the CEA
test positive was, however, poor, whereas if the test was negative the probability of
finding LM was low (7%).
We observed that an alteration of liver enzyme values was rather infrequent in
the presence of LM (the best results are obtained by LDH with 51%, see also
median values in Table 4); consistent with most data in the literature, if LM are
small the sensitivity of these tests ranges from 7% to 26%, and improves in direct
relation to the extent of the metastases. All the liver function tests show a good
prediction when negative, but a poor ability of predicting LM when positive. When
we considered the results of all the laboratory tests in each patient (Table 5) we
concluded that, whenever all the tests are normal, the probability of finding LM at
laparotomy is negligible.
If these tests had been used as a criterion for performing further liver investi-
gations, only 2 patients with LM would have avoided 61 (28.5% of the series)
useless examinations. As a matter of fact the 2 cases with LM were undetectable
even with imaging procedures.
If one or more of the tests are abnormal, the probability of finding LM at
laparotomy is directly related to the number of tests altered; the diagnostic
reliability is however very low up to three pathologic tests and becomes satisfactory
only with four or five.
It is clear that the role of laboratory tests is exhausted when suspicion is aroused,
since the surgeon needs further information about the extent, site, number of
metastases and their relationship to biliary and vascular systems, so that an imaging
technique is required.
Our results confirm all the limits of laboratory tests in detecting LM but indicate
a role for them that is as a first step for hepatic evaluation in a patient with primaryCEA AND ENZYMES IN LIVER METASTASES 35
colo-rectal cancer. When the tests are normal further liver investigations could
probably be avoided.
An imaging procedure could, therefore, be reserved only for the proportion of
patients with abnormal tests who must be considered at increased risk of bearing
LM, they must then be carefully studied with preoperative tests (US) and even-
tually with intraoperative US.
References
1. Hughes K.S., Sugarbaker P.H. (1987) Resection of the liver for metastatic solid tumors in
"Surgical treatment of metastatic cancer" Edith Rosenberg S.A., Lippincott J.B. Company.
Philadelphia.
2. Chang A.E., Schneider P.D., Sugarbaker P.H., Simpson C., Culnane M. and Steinberg S.M.
(1987) A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine
chemotherapy in the treatment of colorectal liver metastases. Ann. Surg. 201i, 285-293
3. Tartter P.I., Slater G., Gelerut I. et al. (1981) Screening for liver metastases from colorectal cancer
with carcinoembryonic antigen and alkaline phosphatase. Ann. Surg. 193, 357-360.
4. Baden H., Andersen B., Angustenberg G. et al. (1971) Diagnostic value of GGT and alkaline
phosphatase in liver metastases. Surg. Gynecol. Obstet. 133, 769.
5. Aronsen K.F., Nosslin B., Pihl. (1970) The value of gamma-glutamul transpeptidase as a screen
test for liver tumour. Acta. Chir. Scand..1311, 17-22.
6. Gennari L., Doci R., Bozzetti F. et al. (1982) Proposal for a clinical classification of liver
metastases. Tumori I18, 443-449.
7. Snow J.H., Goldstein H.M., Wallace S. (1979) Comparison of scintigraphy, sonography and
computed tomography in the evaluation of hepatic imaging in the detection of metastatic
neoplasm. Am. J. Rad. 132, 915-918.
8. Smith T.J., Kemeny M.M., Sugarbaker P.H et al. (1982) A prospective study of hepatic imaging in
the detection of metastatic disease. Ann. Surg. 195,486-491.
9. Arnaud J.P., Daly R., Leguillon A. et al. (1982) Etude comparative de l’ecography et de las
scintigraphie dans le depistage des metastases hepatiques. J. Radiol. 1i3, 97-100.
10. Drum DE. (1978) Optimizing the clinical value of hepatic scintigraphy. Semin. Nucl. Med. 8,346-
357.
11. Kemeny M.M., Sugarbaker P.H., Smith T.J. et al. (1982) A prospective analysis of laboratory tests
and imaging studies to detect hepatic lesion. Ann. Surg. 195, 163-169.
12. McCartney W.H., Hoffer P.B. (1976) Carcinoembryonic antigen assay in hepatic metastases
detection, an adjunct to liver scanning. JAMA 2311, 1023-1027.
13. Munjal D., Chawla P.L., Lokich J.J. et al. (1976) Carcinoembryonic antigen and phosphohexose
isomerase, gamma glutamyl transpeptidase and lactate dehydrogenase levels in patients with and
without liver metastases. Cancer 37, 1800-1807.
14. Schaefer J., Schiff L. (1965) Liver function tests in metastatic tumor of the liver: study of 100 cases.
Gastroenterol. 49, 360-363.
15. Schreve., Terpostra O.T., Ausema L. et al. (1984) Detection of liver metastases. A prospective
study comparing liver enzymes, scintigraphy, ultrasonography and computed tomography. Br. J.
Surg. 71,435-438.
16. Graffuer H, Hultberg., Johansson B. et al. (1985) Detection of recurrent cancer of the colon-
rectum. J. Surg. Oncol. 28, 156-159.
17. Ranson J.H.C., Adams P.K., Localio S.A. (1973) Preoperative assessment for hepatic metastases
in carcinoma of the colon and rectum. Surg. Gynecol. Obstet. 137, 435-438.
18. Kemeny M.M., Gantlaume L., Goldberg D.A. (1986) Preoperative staging with computerized
axial tomography and biochemical laboratory tests in patients with hepatic metastases. Ann. Surg.
21}3, 169-172.
19. Steele L., Cooper E.H., Mackay A.M. et al. (1974) Combination ofCEA and GGT in the study of
the evaluation of colorectal cancer. Br. J. Cancer 30, 319-324.
20. Finlay I.G., McArdle C.S. (1986) Occult hepatic metastases in colorectal carcinoma. Br. J. Surg.
73, 732-735.
21. Machi J. Isomoto H., Yamashita Y. et al. (1987) Intraoperative ultrasonography in screening for
liver metastases from colorectal cancer: comparative accuracy with traditional procedures. Surgery
101,678-684.36 G. BONFANTI ETAL.
22. Gigot J.F., De Neve De Roden A., Weerts J. et al. (1988) Intraoperative ultrasound in the
detection of occult metastases in colorectal cancer surgery: a prospective multicentric study.
Personal communication 2nd World Congress on Hepato-Pancreato Biliary Surgery, Amsterdam
May 29-June 3.
(Accepted by S. Bengmark on 20 December 1989)
INVITED COMMENTARY
"The role ofCEA and liver function tests in the detection of hepatic metastases from colo-rectal cancer"
This is a retrospective review of 278 patients admitted to the Institute Nazionale
Tumori for primary colorectal cancer over a 2 year period. Thirty eight of these
patients were found to have liver metastases on laparotomy and this study analyzes
how accurately the preoperative laboratory tests predicted this outcome. Not
unexpectedly CEA was the most sensitive at 71%, but not the most specific (70%)
since often patients with primary colon cancer will have elevated CEA levels with
or without liver metastases. The rest of the liver function tests were much less
sensitive ranging from 32-51%. The only imaging test studied was ultrasonography
(US) done in 113 of the 278 patients. Even in this more select group US only had a
sensitivity of 50%.
When the 38 cases with liver metastases were broken down into the Gennari
classification of extension of liver involvement it was clear that the greater the
involvement the more sensitive the tests. For instance CEA had 62% sensitivity in
the H1 category, versus 100% and 75% in the H2 and H3 categories. For liver
function tests the sensitivity plummets when there is minimal disease. Alkaline
phosphatase has a 10% sensitivity in the H1 category versus 89% in the H3 group.
The last point brought out by this study dealt with the predictive value of
pathologic tests in relation to how many tests were abnormal. Thus in the 5 cases
which had all five tests abnormally elevated all five patients had liver metastases
thus a predictive value of 100%. If only one test was abnormal the predictive value
was 12.8%, if two 15.4%, three 22.7%, and four 80%.
This study very much corroborates a number of previous studies including ones I
have published with my colleagues (references in the Bonfanti paper). Although in
my prospective work I found a higher sensitivity rate for alkaline phosphatase,
CEA and LDH (61%, 83% and 58% respectively) the general conclusions of the
studies were the same. CEA was the most sensitive laboratory test. Liver function
tests were not sensitive as screening tools especially for minimal liver metastases,
but if all or most of the tests were elevated the probability of having liver
metastases was much higher. The greater the extent of liver disease the more likely
there is some biochemical abnormality.
It seems the ultrasound in the Milan group was unusually unsensitive at 50%
even in their more select group while we saw a sensitivity of 61% in a prospective
group. I don’t know the reason for this difference, although Dr. Bonfanti explains
it by the fact that the metastases were very small in his group.
I agree with the conclusion of Dr. Bonfanti et al. that if none of the liver function
tests or the CEA are elevated further investigation is not warranted. However it
must be kept in mind that in my study and the Milan study there were patients withCEA AND ENZYMES IN LIVER METASTASES 37
liver metastases and totally normal laboratory tests. The advance of more sensitive
imaging procedures will help us in the future to detect disease before operation. A
large step in sensitivity has been gained in the combined CT angiogram sometimes
called dynamic portography. However this is an invasive test and should be
reserved for the situations where all other tests have not been useful. The gold
standard still remains exploratory surgery with bimanual palpation of the liver.
Intraoperative ultrasound, which Dr. Gennari’s group reported on several years
ago also increases the surgeons ability to detect metastases at laparotomy especially
those small deep lesions which cannot be palpated well and in cases of cirrhosis
where palpation is all but useless. Dr. Bonfanti reports that of all the patients with
no evidence of liver metastases at laparotomy and normal tests (59 patients) two
developed liver metastases at 10 and 12 months after operation, thus reconfirming
the accuracy of intraoperative examination. It is disheartening that in 1990 we are
still drawing the same conclusions about the same tests as we did in 1982, however
we as clinicians have to wait till either monoclonal antibody technology for imaging
tests or some more specific biochemical marker comes along so that our preopera-
tive accuracy can rise to the more acceptable range of 85-90 percent. Till then no
matter how we try to analyze the data we do not have an acceptable, accurate
screening tool for detecting liver metastases in patients with colorectal cancer.
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